BIOLARGO, INC. (BLGO) — Quarterly Report

Key Insights

• Stock price severely depressed at $0.16 per share as of March 31, 2026, indicating significant shareholder value destruction and potential financial distress concerns.
• Company maintains multi-subsidiary structure (Clyra Medical Technologies, BioLargo Energy Technologies) with complex ownership interests, suggesting ongoing portfolio diversification but raising integration and capital allocation questions.
• Large authorized share count (550 million shares) relative to issued shares (319.7 million) indicates substantial dilution risk from potential future equity issuances to fund operations.
• Customer concentration evident across revenue streams with identified customer A-E members, creating material revenue dependency risk if major customers reduce orders or cease relationships.